Arrowhead Stock Analysis

ARWR -  USA Stock  

USD 85.64  0.34  0.40%

The latest spike in Arrowhead Pharma short term price appreciation could raise concerns from retail investors as the firm it trading at a share price of 85.64 on 1,264,600 in volume. The company management teams have successfully maneuvered the firm at convenient times to take advantage of all market conditions in May. The stock standard deviation of daily returns for 90 days investing horizon is currently 2.79. The current volatility is consistent with the ongoing market swings in May 2021 as well as with Arrowhead Pharma unsystematic, company-specific events.
Please continue to Trending Equities.

Search Stock Analysis 

The Arrowhead Pharma stock analysis report makes it easy to digest most publicly released information about Arrowhead Pharma and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Arrowhead stock analysis module also helps to analyze the Arrowhead Pharma price relationship with some important fundamental indicators such as market cap and management efficiency.

Arrowhead Stock Analysis Notes

About 67.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings (P/E) ratio of 482.39. Arrowhead Pharma recorded a loss per share of 1.0. The entity next dividend is scheduled to be issued on the 29th of October 2010. The firm had 1:10 split on the 17th of November 2011. Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California. Arrowhead Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 232 people. For more info on Arrowhead Pharma please contact Christopher Anzalone at 626 304-3400 or go to

Arrowhead Pharma Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Arrowhead Pharma's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Arrowhead Pharma or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
The company reported the previous year's revenue of 79.84 M. Net Loss for the year was (102.61 M) with profit before overhead, payroll, taxes, and interest of 87.99 M.
Arrowhead Pharma currently holds about 305.33 M in cash with (110.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.94.
Roughly 67.0% of the company shares are held by institutions such as insurance companies
Latest headline from Arrowhead Pharmaceuticals Inc. falls -2.0130 percent for June 15 -

Arrowhead Pharma Upcoming and Recent Events

Earnings reports are used by Arrowhead Pharma to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Arrowhead Pharma previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report4th of August 2021
Next Earnings Report22nd of November 2021
Next Fiscal Quarter End30th of June 2021
Next Fiscal Year End22nd of November 2021
Last Quarter Report31st of March 2021
Last Earning Announcement30th of June 2020

Arrowhead Largest EPS Surprises

Earnings surprises can significantly impact Arrowhead Pharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Arrowhead Pharma SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Arrowhead Pharma prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Arrowhead Pharma investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Arrowhead Pharma specific information freely available to individual and institutional investors to make a timely investment decision.
4th of May 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
24th of March 2021
Financial Statements and Exhibits. Submission of Matters to a Vote of Security Holders. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
10th of February 2021
Unclassified Corporate Event
4th of February 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
27th of January 2021
Unclassified Corporate Event
23rd of November 2020
Financial Statements and Exhibits. Results of Operations and Financial Condition
9th of October 2020
Financial Statements and Exhibits. Entry into a Material Definitive Agreement
8th of September 2020
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Arrowhead Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Arrowhead Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Arrowhead Pharma backward and forwards among themselves. Arrowhead Pharma's institutional investor refers to the entity that pools money to purchase Arrowhead Pharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Blackrock IncCommon Shares12.9 M855.5 M
Vanguard Group IncCommon Shares9.6 M636.7 M
State Street CorpCommon Shares3.7 M247.6 M
Invesco LtdCommon Shares3.4 M224.9 M
Johnson Johnson InnovatioCommon Shares3.3 M216.2 M
Jpmorgan Chase CoCommon Shares2.6 M170.6 M
Geode Capital Management LlcCommon Shares1.8 M116.5 M
Note, although Arrowhead Pharma's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Arrowhead Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 8.89 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Arrowhead Pharma's market, we take the total number of its shares issued and multiply it by Arrowhead Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Arrowhead Profitablity

Arrowhead Pharma's profitability indicators refer to fundamental financial ratios that showcase Arrowhead Pharma's ability to generate income relative to its revenue or operating costs. If, let's say, Arrowhead Pharma is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Arrowhead Pharma's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Arrowhead Pharma's profitability requires more research than a typical breakdown of Arrowhead Pharma's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (128.52) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (140.73) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -1.41.
Last ReportedProjected for 2021
Return on Investment(23.74) (25.62) 
Return on Average Assets(0.17) (0.18) 
Return on Average Equity(0.20) (0.22) 
Return on Invested Capital(0.46) (0.49) 
Return on Sales(1.22) (1.32) 

Management Efficiency

The entity has return on total asset (ROA) of (12.92) % which means that it has lost $12.92 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (21.51) %, meaning that it created substantial loss on money invested by shareholders. Arrowhead Pharma management efficiency ratios could be used to measure how well arrowhead pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of 06/19/2021, Return on Investment is likely to drop to -25.62. In addition to that, Return on Average Assets is likely to drop to -0.18. Arrowhead Pharma Total Assets are relatively stable at the moment as compared to the past year. Arrowhead Pharma reported last year Total Assets of 600.88 Million. As of 06/19/2021, Current Assets is likely to grow to about 400 M, while Revenue to Assets are likely to drop 0.13.
Last ReportedProjected for 2021
Book Value per Share 5.27  5.69 
Enterprise Value over EBIT(40.50) (41.56) 
Enterprise Value over EBITDA(43.12) (44.26) 
Price to Book Value 10.97  9.69 
Tangible Assets Book Value per Share 5.79  6.25 
Enterprise Value4.8 B5.2 B
Tangible Asset Value583.2 M629.3 M

Technical Drivers

As of the 19th of June, Arrowhead Pharma shows the Downside Deviation of 2.77, mean deviation of 2.17, and Risk Adjusted Performance of 0.0754. Arrowhead Pharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We are able to interpolate and break down nineteen technical drivers for Arrowhead Pharma, which can be compared to its rivals. Please confirm Arrowhead Pharma standard deviation, value at risk, as well as the relationship between the Value At Risk and kurtosis to decide if Arrowhead Pharma is priced correctly, providing market reflects its regular price of 85.64 per share. Given that Arrowhead Pharma has jensen alpha of 0.2906, we suggest you to validate Arrowhead Pharma's prevailing market performance to make sure the company can sustain itself at a future point.

Arrowhead Pharma Price Movement Analysis

The output start index for this execution was nineteen with a total number of output elements of fourty-two. The Mid-point over period is an average of Arrowhead Pharma highest and lowest values attained during the given period. View also all equity analysis or get more info about midpoint over period overlap studies indicator.

Arrowhead Pharma Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Arrowhead Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Arrowhead Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Arrowhead Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Douglas Given over three months ago via Macroaxis 
Arrowhead Pharma exotic insider transaction detected
Patrick OBrien over three months ago via Macroaxis 
Exercise or conversion by Patrick OBrien of 90000 shares of Arrowhead Pharma subject to Rule 16b-3
Hamilton James C over three months ago via Macroaxis 
Sale by Hamilton James C of 3814 shares of Arrowhead Pharmaceuticals
Kenneth Myszkowski over three months ago via Macroaxis 
Sale by Kenneth Myszkowski of 1441 shares of Arrowhead Pharmaceuticals
Hassard James over three months ago via Macroaxis 
Sale by Hassard James of 15625 shares of Arrowhead Pharmaceuticals
Hamilton James C over three months ago via Macroaxis 
Sale by Hamilton James C of 14708 shares of Arrowhead Pharmaceuticals
Hamilton James C over three months ago via Macroaxis 
Acquisition by Hamilton James C of 50000 shares of Arrowhead Pharmaceuticals subject to Rule 16b-3
Christopher Anzalone over three months ago via Macroaxis 
Acquisition by Christopher Anzalone of 800000 shares of Arrowhead Pharmaceuticals subject to Rule 16b-3
Christopher Anzalone over three months ago via Macroaxis 
Bona fide gift to Christopher Anzalone of 1126 shares of Arrowhead Pharmaceuticals subject to Section 16
Douglas Given over three months ago via Macroaxis 
Bona fide gift to Douglas Given of tradable shares of Arrowhead Pharmaceuticals subject to Section 16
Christopher Anzalone over three months ago via Macroaxis 
Exercise or conversion by Christopher Anzalone of 28274 shares of Arrowhead Pharmaceuticals subject to Rule 16b-3
William Waddill over six months ago via Macroaxis 
Sale by William Waddill of 1800 shares of Arrowhead Pharmaceuticals

Arrowhead Pharma Predictive Daily Indicators

Arrowhead Pharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Arrowhead Pharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Arrowhead Pharma Forecast Models

Arrowhead Pharma time-series forecasting models is one of many Arrowhead Pharma's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Arrowhead Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Arrowhead Pharma Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Arrowhead Pharma stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Arrowhead shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Arrowhead Pharma. By using and applying Arrowhead Stock analysis, traders can create a robust methodology for identifying Arrowhead entry and exit points for their positions.
Last ReportedProjected for 2021
Operating Margin 32.63  32.44 
EBITDA Margin(1.15) (1.24) 
Gross Margin 0.90  0.89 
Profit Margin(1.11) (1.19) 
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The companys products in pipeline includes ARO-AAT, a RNA interference therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency ARO-APOC3, which is in Phase III clinical trial to treat hypertriglyceridemia ARO-ANG3 that is in Phase III clinical trial to reduce production of angiopoietin-like protein 3 ARO-HSD, which is in Phase III clinical trial for treating liver diseases ARO-ENaC, which is in Phase III clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens and ARO-HIF2, which is in phase Ib for the treatment of clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection Olpasiran to reduce production of apolipoprotein A and ARO-AMG1 for treating genetically validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Current Arrowhead Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Arrowhead analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Arrowhead analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
Arrowhead Pharma current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Arrowhead analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Arrowhead stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Arrowhead Pharma, talking to its executives and customers, or listening to Arrowhead conference calls.
Arrowhead Analyst Advice Details

Arrowhead Stock Analysis Indicators

Arrowhead Pharma stock analysis indicators help investors evaluate how Arrowhead Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Arrowhead Pharma shares will generate the highest return on investment. By understating and applying Arrowhead Pharma stock analysis, traders can identify Arrowhead Pharma position entry and exit signals to maximize returns.
Quick Ratio12.53
Fifty Two Week Low32.86
Revenue Growth-27.70%
Shares Short Prior Month5.13M
Average Daily Volume Last 10 Day828.86k
Average Daily Volume In Three Month735.63k
Shares Percent Shares Out4.62%
Gross Margins100.00%
Short Percent Of Float5.41%
Forward Price Earnings-285.47
Float Shares100.46M
Fifty Two Week High92.60
Enterprise Value To Ebitda-62.51
Fifty Day Average74.47
Two Hundred Day Average74.89
Enterprise Value To Revenue82.86
Please continue to Trending Equities. Note that the Arrowhead Pharma information on this page should be used as a complementary analysis to other Arrowhead Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Content Syndication module to quickly integrate customizable finance content to your own investment portal.

Complementary Tools for Arrowhead Pharma Stock analysis

When running Arrowhead Pharma price analysis, check to measure Arrowhead Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharma is operating at the current time. Most of Arrowhead Pharma's value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Arrowhead Pharma's price. Additionally, you may evaluate how the addition of Arrowhead Pharma to your portfolios can decrease your overall portfolio volatility.
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
CEO Directory
Screen CEOs from public companies around the world
The market value of Arrowhead Pharma is measured differently than its book value, which is the value of Arrowhead that is recorded on the company's balance sheet. Investors also form their own opinion of Arrowhead Pharma's value that differs from its market value or its book value, called intrinsic value, which is Arrowhead Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arrowhead Pharma's market value can be influenced by many factors that don't directly affect Arrowhead Pharma underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arrowhead Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Arrowhead Pharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arrowhead Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.